Affymetrix reports total revenue of $73.
Affymetrix reports total revenue of $73.7 million for first quarter 2011 Affymetrix, Inc., today reported its operating results for the first one fourth of 2011 SilagraCipla.net . Total income for the quarter was $73.7 million, when compared with total revenue of $80.2 million in the first quarter of 2010. The ongoing company reported hook profit in the first quarter of 2011. This compares to net loss of $9.6 million, or $0.14 per diluted talk about, in the same period of 2010. For the first one fourth of 2011, product income was $67.5 million, which contains consumable revenue of $62.9 million and instrument revenue of $4.6 million. Support revenue was $4.5 million, and royalties and other revenue was $1.7 million.
Related StoriesNew findings reveal association between colorectal tumor and melanoma medication treatmentMeat-rich diet may boost kidney tumor riskFDA grants accelerated acceptance for Tagrisso to take care of individuals with advanced NSCLC We are thrilled to increase our relationship with Affymetrix through this unique product, said Dr. Soheil Shams, BioDiscovery's Chief Scientific Officer. The top quality data from the Affymetrix assays performs very well in our software program for detecting copy number variants. We have customers all over the world which have been leveraging the CytoScan Cytogenetics Suite and OncoScan systems for copy number evaluation from various kinds of malignancy samples, and we're very happy to be able to present this joint solution to greatly help scientists to get further insights into malignancy biology.